ChiCTR2200059365 版本V1.0 版本创建时间2022/04/28 11:44:25 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2200059365 

最近更新日期:

Date of Last Refreshed on:

2022-04-28 11:44:18 

注册时间:

Date of Registration:

2022-04-28 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

该研究尚未获得伦理委员会批准,请于批准后再开始纳入参试者,并与我们联系上传文件;请上传研究计划书。 电视辅助胸腔镜与开胸肺叶切除术治疗肺癌患者的疗效比较:一项单中心随机对照研究

Public title:

Evaluation on curative effects of video-assisted thoracoscopic surgery versus thoracotomy lobectomy for patients with lung cancer: study protocol for a single-center randomized controlled trial

注册题目简写:

English Acronym:

研究课题的正式科学名称:

电视辅助胸腔镜与开胸肺叶切除术治疗肺癌患者的疗效比较:一项单中心随机对照研究

Scientific title:

Evaluation on curative effects of video-assisted thoracoscopic surgery versus thoracotomy lobectomy for patients with lung cancer: study protocol for a single-center randomized controlled trial

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

马俊杰 

研究负责人:

马骏 

Applicant:

Junjie Ma 

Study leader:

Jun Ma 

申请注册联系人电话:

Applicant telephone:

18635518221

研究负责人电话:

Study leader's
telephone:

13835538933

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

mmjj362112@aliyun.com

研究负责人电子邮件:

Study leader's E-mail:

13835538933@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

山西省长治市太行东街271号

研究负责人通讯地址:

山西省长治市太行东街271号

Applicant address:

271 Taihang East Street, Changzhi City, Shanxi Province, China

Study leader's address:

271 Taihang East Street, Changzhi City, Shanxi Province, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

长治医学院附属和济医院

Applicant's institution:

Changzhi Medical College Affiliated Heji Hospital

研究负责人所在单位:

Affiliation of the Leader:

是否获伦理委员会批准:

Approved by ethic committee:

No

伦理委员会批件文号:

Approved No. of ethic committee:

伦理委员会批件附件:

Approved file of Ethical Committee:

批准本研究的伦理委员会名称:

Name of the ethic committee:

伦理委员会批准日期:

Date of approved by ethic committee:

2013-08-26 00:00:00

伦理委员会联系人:

Contact Name of the ethic committee:

伦理委员会联系地址:

Contact Address of the ethic committee:

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

长治医学院附属和济医院

Primary sponsor:

Changzhi Medical College Affiliated Heji Hospital

研究实施负责(组长)单位地址:

山西省长治市太行东街271号

Primary sponsor's address:

271 Taihang East Street, Changzhi City, Shanxi Province, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

山西

市(区县):

长治

Country:

China

Province:

Shanxi

City:

Changzhi

单位(医院):

长治医学院附属和济医院

具体地址:

山西省长治市潞州区太行东街271号

Institution
hospital:

Changzhi Medical College Affiliated Heji Hospital

Address:

271 Taihang East Street, Luzhou District, Changzhi, Shanxi

经费或物资来源:

自选课题(自筹)

Source(s) of funding:

Self-selected topics (self-funded)

研究疾病:

肺癌  

Target disease:

Lung cancer

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

评价电视胸腔镜辅助肺切除术与开胸肺切除术的近期疗效及其对患者肺功能的影响  

Objectives of Study:

To evaluate the short-term efficacy of video-assisted thoracoscopic pneumonectomy and thoracotomy and its effect on lung function

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

(1)年龄小于等于75岁;
(2)患者既往无恶性肿瘤病史;
(3)胸部CT提示无肺门和纵膈淋巴结转移(淋巴结短径小于等于1cm)的肺癌;
(4)心肺肝肾等主要器官功能无开胸肺叶切除禁忌;
(5)术前未接受放化疗或靶向药物治疗的患者;
(6)患者自愿参与并签署知情同意书。

Inclusion criteria

(1) The age is less than or equal to 75 years old;
(2) The patient had no previous history of malignant tumor;
(3) Chest CT showed lung cancer without hilar and mediastinal lymph node metastasis (the short diameter of lymph nodes is less than or equal to 1cm);
(4) There is no contraindication of thoracotomy lobectomy for the function of main organs such as heart, lung, liver and kidney;
(5) Patients who did not receive radiotherapy, chemotherapy or targeted drug therapy before operation;
(6) Patients voluntarily participated and signed informed consent.

排除标准:

(1)年龄大于75岁;
(2)患者既往有其它恶性肿瘤疾病史;
(3)肿瘤直径大于6cm且侵犯胸壁者;
(4)排除合并严重躯体性疾病者;
(5)术前接受其它形式的抗肿瘤治疗(放疗或化疗)。

Exclusion criteria:

(1) Over 75 years old;
(2) The patient had a history of other malignant tumor diseases in the past;
(3) The tumor diameter was more than 6cm and invaded the chest wall;
(4) Patients with severe somatic diseases were excluded;
(5) Receive other forms of antitumor treatment (radiotherapy or chemotherapy) before operation.

研究实施时间:

Study execute time:

From 2022-04-25 00:00:00 To 2023-04-28 00:00:00  

征募观察对象时间:

Recruiting time:

From 2022-04-25 00:00:00 To 2023-04-28 00:00:00

干预措施:

Interventions:

组别:

治疗组

样本量:

35

Group:

Treatment group

Sample size:

干预措施:

电视辅助胸腔镜

干预措施代码:

Intervention:

Video-assisted thoracoscopic surgery

Intervention code:

组别:

对照组

样本量:

35

Group:

Control group

Sample size:

干预措施:

开胸肺切除

干预措施代码:

Intervention:

Thoracotomy lobectomy

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

山西 

市(区县):

长治 

Country:

China

Province:

Shanxi

City:

Changzhi

单位(医院):

长治医学院附属和济医院 

单位级别:

三甲 

Institution
hospital:

Changzhi Medical College Affiliated Heji Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

手术时间

指标类型:

主要指标

Outcome:

Operation time

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

胸腔引流量

指标类型:

主要指标

Outcome:

Thoracic drainage

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

术中出血量

指标类型:

主要指标

Outcome:

Intraoperative bleeding

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

引流管放置时间

指标类型:

次要指标

Outcome:

Drainage tube placement time

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

术后住院时间

指标类型:

次要指标

Outcome:

Postoperative hospital stay

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

并发症发生率

指标类型:

次要指标

Outcome:

Incidence of complications

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 75 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

由患者家属进行抽签随机分组

Randomization Procedure (please state who generates the random number sequence and by what method):

Patients' families were randomly divided into groups by lot

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

联系项目负责人

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Contact the project leader

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

CRF表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

CRF table

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2022-04-28 11:44:18